摘要
目的:探讨阿帕替尼致高血压的临床特点,为临床防治提供参考。方法:从知网、PubMed等国内外数据库检索阿帕替尼致高血压的病例报告文献,分析患者基本情况、抗肿瘤治疗方案、高血压发生、干预和转归等情况。结果:收集到26篇文献,患者共30例;男性12例,女性18例;年龄16~93岁,平均58岁。阿帕替尼日剂量500 mg和250 mg最普遍。19例高血压发生的中位时间为14(7,30)d,其中13例(68%)出现在服药15 d内。3级及以上高血压16例(53%),手足综合征和蛋白尿是常见的并发不良反应。绝大多数患者经阿帕替尼剂量调整和/或降压治疗后血压控制平稳,仅4例患者停用阿帕替尼。结论:阿帕替尼致高血压多在用药2周内出现,3级及以上高血压常见,但多数患者的血压经阿帕替尼停药或减量治疗和应用降压药后可控。
Objective:To investigate the clinical features of apatinib-associated hypertension to provide reference for clinical prevention and treatment.Methods:The case report literature related to apatinib induced hypertension was retrieved from domestic and foreign databases such as CNKI and PubMed and basic characteristics of patients,anti-tumor regimen,situation of hypertension,interventions and outcomes were analyzed.Results:A total of 26 literature and 30 patients were involved in the analysis,including 12 males and 18 females.Their ages were between 16 to 93 years old with a mean of 58.The most common daily doses of apatinib were 500 mg or 250 mg.The median onset time of hypertension in 19 cases was 14(7,30)days,in which 13 cases(68%)occurred within 15 days after taking apatinib.Hypertension with grade 3 or above was observed in 16 cases(53%),hand-foot syndrome and proteinuria were common adverse reactions.Most patients had stable blood pressure control after the adjustment of apatinib dose and/or antihypertensive therapy,and apatinib was discontinued only in 4 patients.Conclusion:Apatinib-associated hypertension usually occurs within 2 weeks after medication,and the hypertension with grade 3 or above is common,but the blood pressure of most patients can be controlled after stopping apatinib or reducing its dose and applying antihypertensive drugs.
作者
王春晖
吴薇
张皓云
许青
WANG Chunhui;WU Wei;ZHANG Haoyun;XU Qing(Zhongshan Hospital,Fudan University,Shanghai 200032,China;School of Pharmacy,Fudan University,Shanghai 201203,China)
出处
《上海医药》
CAS
2024年第13期52-56,共5页
Shanghai Medical & Pharmaceutical Journal
基金
上海市临床重点专科项目(shslczdzk06504)
上海市医苑新星青年医学人才培养资助计划项目
复旦大学附属中山医院管理科学基金项目(2021ZSGL08)。
